PR Newswire
HOLON, Israel, December 7, 2016
HOLON, Israel, December 7, 2016 /PRNewswire/ --
Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug discovery company, announced today the following key highlights from
its R&D Day that took place this morning in NYC:
- Disclosure of a therapeutic antibody program targeting TIGIT to complement the Company's CGEN-15029 program, following new
data recently generated for the CGEN-15029/PVRIG program. TIGIT and PVRIG represent two distinct arms of the same biological
pathway. Based on this and experimental data, the Company believes there is significant added value to developing both arms as
a potential combination therapy. Compugen expects to select the lead antibody for CGEN-15137/TIGIT by end of Q1 2017.
- COM701, clinical candidate antibody targeting CGEN-15029/PVRIG, is currently undergoing process development as part of the
manufacturing activities to generate clinical material. IND-filing for COM701 is anticipated in Q4 2017.
- Update on status of cancer immunotherapy partnership with Bayer entered in August 2013. As
previously disclosed, after achieving all preclinical stage milestones for CGEN-15001T immune checkpoint, this program was
transferred to Bayer for further development. To date, preclinical activities are on track, and pivotal toxicity studies and
GMP clinical trial material production are ongoing. As previously disclosed, the second program under the partnership,
CGEN-15022, is at an earlier stage and further characterization studies of its role in anti-cancer immune responses are
ongoing.
- Disclosure of a new therapeutic program focusing on a protein target expressed in various cancers, and which is highly
correlated with an M2 macrophages marker. The target was also shown to inhibit T cell activation in cell-based studies.
Macrophages are immune cells that are highly immune suppressive in the tumor microenvironment, and targeting such cells offers
the potential for efficacy in patients non-responsive to checkpoint inhibitors. Therapeutic antibody discovery activities have
been initiated for this program.
- Overview of the Company's immuno-oncology target validation pipeline activities, which primarily focus on myeloid targets.
With an aim to complement and expand the patient population responsive to checkpoints inhibitors, blocking myeloid targets may
serve as the next wave of cancer immunotherapies. Myeloid CGEN-target candidates have been identified within the tumor
microenvironment of multiple cancers and are aggressively pursued by the Company and in collaboration with Prof. Drew Pardoll.
- The event also featured a presentation by Prof. Drew Pardoll, Chairman of Compugen's
Scientific Advisory Board and Abeloff Professor of Oncology, Medicine, Pathology and Molecular Biology and Genetics at
Johns Hopkins University of Medicine, and Director of the Bloomberg~Kimmel Institute for Cancer
Immunotherapy at the Sidney Kimmel Cancer Center, Johns Hopkins. The presentation included an
overview of the immune checkpoint inhibition landscape, including both T cells and myeloid cells. Prof. Pardoll further
presented in vitro and in vivo data demonstrating the importance of PVRIG/CGEN-15029 as a significant T cell
immune checkpoint as well as evidences that PVRIG-blockage synergizes with PD1/PDL1 in unleashing T cell activity.
About Compugen
Compugen is a leading therapeutic discovery company utilizing its broadly applicable predictive discovery infrastructure to
identify novel drug targets and develop first-in-class biologics. The primary focus of the Company's current pipeline is on
immune checkpoint target candidates discovered by the Company, potentially providing the basis for a next wave of therapeutics
for cancer immunotherapy. Compugen's business model is based on selectively entering into collaborations for its novel target
candidates and drug product candidates at various stages of research and development under revenue-sharing agreements. The
Company is headquartered in Israel, with R&D facilities in Israel and South San Francisco. At the US facilities, monoclonal antibody therapeutic candidates are
discovered and developed against the Company's novel target candidates. For additional information, please visit Compugen's
corporate website at http://www.cgen.com.
Forward Looking Statement
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements can be identified by the use of terminology such as "will," "may," "expects," "anticipates,"
"believes," and "intends," and describe opinions about future events, and include statements relating to the potential of the
CGEN-15029 program for the development of new cancer immunotherapy treatments, including the potential of COM701 alone or
combined with anti-CGEN-15137 antibody as a new cancer immunotherapy treatment. These forward-looking statements involve known
and unknown risks and uncertainties that may cause the actual results, performance or achievements of Compugen to be materially
different from any future results, performance or achievements expressed or implied by such forward-looking statements. Among
these risks: Compugen's business model is substantially dependent on entering into collaboration agreements with third parties,
and Compugen may not be successful in generating adequate revenues or commercializing aspects of its business model. Moreover,
the development and commercialization of therapeutic candidates involve many inherent risks, including failure to progress to
clinical trials or, if they progress to or enter clinical trials, failure to receive regulatory approval. These and other factors
are more fully discussed in the "Risk Factors" section of Compugen's most recent Annual Report on Form 20-F as filed with the
Securities and Exchange Commission as well as other documents that may be subsequently filed by Compugen from time to time with
the Securities and Exchange Commission. In addition, any forward-looking statements represent Compugen's views only as of the
date of this release and should not be relied upon as representing its views as of any subsequent date. Compugen does not assume
any obligation to update any forward-looking statements unless required by law.
Company contact:
Tsipi Haitovsky
Global Media Liaison
Compugen Ltd.
Email: tsipih@cgen.com
Tel: +972-52-598-9892
SOURCE Compugen Ltd.
